ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January

ProQR Therapeutics N.V. (NASDAQ:PRQR) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 1,785,809 shares, an increase of 47.2% from the January 15th total of 1,213,326 shares. Based on an average daily volume of 439,616 shares, the days-to-cover ratio is presently 4.1 days. Currently, 1.9% of the company’s stock are short sold. Currently, 1.9% of the company’s stock are short sold. Based on an average daily volume of 439,616 shares, the days-to-cover ratio is presently 4.1 days.

Institutional Trading of ProQR Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Walleye Capital LLC increased its stake in ProQR Therapeutics by 11.2% in the 4th quarter. Walleye Capital LLC now owns 591,785 shares of the biopharmaceutical company’s stock worth $1,195,000 after buying an additional 59,808 shares during the period. Jane Street Group LLC raised its holdings in shares of ProQR Therapeutics by 1,388.5% in the 4th quarter. Jane Street Group LLC now owns 160,175 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 149,414 shares in the last quarter. Simplex Trading LLC lifted its position in shares of ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 44,169 shares during the period. Geode Capital Management LLC grew its stake in ProQR Therapeutics by 73.9% in the fourth quarter. Geode Capital Management LLC now owns 84,909 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 36,087 shares during the last quarter. Finally, Privium Fund Management B.V. grew its stake in ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after purchasing an additional 359,475 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Finally, Chardan Capital reiterated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.14.

ProQR Therapeutics Stock Performance

PRQR stock traded up $0.07 during trading on Monday, hitting $1.46. 354,933 shares of the company’s stock traded hands, compared to its average volume of 392,090. The stock has a market capitalization of $153.61 million, a price-to-earnings ratio of -3.11 and a beta of 0.20. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $3.10. The business has a fifty day simple moving average of $1.87 and a 200 day simple moving average of $2.13.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.